Sources Sought Notice

The Defense Logistics Agency Troop Support is seeking sources capable of providing Reactive Skin Decontamination Lotion (RSDL) NSN 6505-01-507-5074. Shall be a topical lotion containing a free oxime dissolved in a maximum of polyethylene glycol monomethyl ether and water. It is intended to remove or neutralize chemical warfare (CW) agents, including many organophosphate-based pesticides and T-2 toxin from the skin. Shall be pre-impregnated in a suitable sponge applicator pad. Each applicator pad shall be individually packaged in a heat sealed polyethylene-lined aluminum foil pouch. The foil pouch shall permit easy opening of the package when wearing CW protective clothing. Shall be cleared for use by the United States (U.S.) Food and Drug Administration (FDA) for application on unbroken skin of hands, face, neck, limbs and torso. The manufacturer shall also provide an Inactive Skin Decontamination Lotion (ISDL) NSN 6910-01-507-5141. ISDL is a training lotion that imitates the properties of the decontamination lotion in all but active decontaminating ingredients.

DLA Troop Support has annual estimated requirements for RSDL of 13,249 packages and annual estimated requirements for ISDL of 460 packages. This contract contains a surge and sustainment requirement for RSDL only.  The annual estimated surge and sustainment requirement is 5,504 packages per month for 6 months; total delivered amount in 6 months is 33,024 packages.  Ordered quantities shall be delivered to military ordering activities or Defense Distribution Centers (DDC) located throughout the U. S.  Delivery shall occur 75 days after receipt of the order.

This is a request for information (RFI) and does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to the RFI. All submitted information shall remain with the U.S. Government and will not returned.

*** Currently Marketed Decontamination Lotion ***

If your firm currently markets decontamination Lotion, please provide information with respects to the following:

•a)      Place of Manufacture

•b)      Estimated Annual Capacity

•c)      FDA registration information

•d)      Product Name and description including description of any special features

•e)      Current unit sale price

•f)       Estimated inventory level and storage requirements

•g)      Delivery days for this item

•h)      Capacity for surge and sustainment requirement

 *** New Products Under Development ***

For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture lotions described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protect Critical infrastructure information (PCII) Program outlined in the Critical Infrastructure Information Act 2002.  

Your response to this RFI should be submitted electronically in pdf format and emailed to Contract Specialist [email protected] before June 17, 2019.